NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.58
+1.40%Oct 9, 2026, 12:56 UTC
Intellia Therapeutics, Inc. shares rose 7.6% in the last session on above-average trading volume.
Source:Oct 1, 2026, 23:59 UTC
The US Food and Drug Administration approved Intellia Therapeutics' biologics license application for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR therapy for hereditary angioedema, in September 2026.
Source:Sep 9, 2026, 15:05 UTC
The FDA accepted Intellia's Biologics License Application for its hereditary angioedema drug lonvo-z and granted it priority review, with a decision expected by March 10, 2027.
Source:Sep 4, 2026, 12:50 UTC
Intellia Therapeutics entered into a non-dilutive debt facility with OrbiMed for up to $400 million, with $75 million funded upfront and an additional $325 million available upon achieving milestones.
Source:Aug 7, 2026, 06:05 UTC
Intellia Therapeutics resumed enrollment in Phase III studies of its gene-editing therapy nex-z for transthyretin amyloidosis during Q2 2026.
Source:Aug 7, 2026, 06:05 UTC
Intellia Therapeutics announced positive Phase III results for its gene-editing therapy lonvo-z in hereditary angioedema during Q2 2026.
Source:Aug 6, 2026, 13:21 UTC
Intellia Therapeutics reported a Q2 2026 loss of $0.8 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.99 per share a year ago.
Jun 15, 2026, 13:39 UTC
Intellia Therapeutics reported additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema.
Source: